Heart Attack Therapies: 30+ Pharma Firms Boost Pipeline
Editorial still life of pharmaceutical research on myocardial infarction.
Key Highlights
Explore the robust heart attack treatment pipeline: Over 30 pharma companies, including Novo Nordisk and AstraZeneca, are developing 40+ novel therapies for myocardial infarction.
Robust Heart Attack Pipeline Emerges
DelveInsight’s latest report reveals a robust pipeline for myocardial infarction (heart attack) treatments, with over 30 pharmaceutical companies actively developing more than 40 therapies. This strong activity signals significant progress in addressing a critical health need.
Key Players & Emerging Drugs
The “Myocardial Infarction Pipeline Insight 2026” report identifies key players driving innovation. Leading firms include Novo Nordisk, Bayer, AstraZeneca, and Faraday Pharmaceuticals. A diverse range of emerging drugs is advancing through clinical trials.
- Faraday Pharmaceuticals’ FDY-5301: A Phase III elemental reducing agent for acute myocardial infarction, targeting ischemia-reperfusion injury.
- Acticor Biotech’s Glenzocimab: A humanized monoclonal antibody fragment in Phase II for myocardial infarction treatment.
- Boehringer Ingelheim’s BI765845: An anti-ischemic agent also undergoing Phase II development.
Ongoing Clinical Studies
Recent initiations further bolster the pipeline. These studies aim to refine existing treatments and introduce new therapeutic approaches.
- Beijing Sungen Biomedical is studying SGC001 to reduce infarct size and inflammation in STEMI patients undergoing PCI.
- University Hospital, Caen, is evaluating Cangrelor’s impact when added to ticagrelor for primary PCI patients with high platelet reactivity.
Understanding Myocardial Infarction
Myocardial infarction, or heart attack, involves irreversible heart muscle necrosis due to prolonged ischemia. This condition typically results from blocked coronary arteries.
Current treatments focus on rapidly restoring blood flow. These methods include medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting.